UBS has upgraded Amgen (AMGN) from neutral to buy, citing promising growth prospects from its late-stage developments, MariTide for obesity and olpasiran for cardiovascular risk reduction. The bank increased its price target for Amgen to $380, representing a 15% upside from Tuesday's close. Analyst Michael Yee highlighted MariTide's potential for monthly dosing and improved tolerability, projecting significant weight loss results. Additionally, olpasiran, a small interfering RNA, is expected to lower lipoprotein(a) for cardiovascular disease treatment.
https://www.gurufocus.com/news/4098427/ubs-upgrades-amgen-amgn-to-buy-raises-price-target-to-380
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.